STOCK TITAN

[144] Cardlytics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Cardlytics, Inc. (CDLX) filed a Form 144 notice reporting a proposed sale of 68,260 common shares through Fidelity Brokerage Services with an aggregate market value of $76,806.15. The filing lists the number of shares outstanding as 53,236,901 and indicates an approximate sale date of 08/18/2025 on NASDAQ. The securities were acquired as restricted stock vesting from the issuer on 08/15/2025 and the payment nature is noted as compensation.

The filer also reported a prior sale on 07/02/2025 of 6,725 shares for gross proceeds of $11,987.99. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Cardlytics, Inc. (CDLX) ha presentato un avviso Form 144 relativo a una proposta di vendita di 68.260 azioni ordinarie tramite Fidelity Brokerage Services per un valore complessivo di $76.806,15. Il deposito riporta il numero di azioni in circolazione pari a 53.236.901 e indica una data di vendita approssimativa del 18/08/2025 sul NASDAQ. I titoli sono stati acquisiti come restricted stock vesting dall'emittente il 15/08/2025 e la natura del pagamento è indicata come compenso.

Il dichiarante segnala inoltre una vendita precedente avvenuta il 02/07/2025 di 6.725 azioni per ricavi lordi di $11.987,99. Il deposito include la dichiarazione standard secondo cui il venditore non è a conoscenza di informazioni materiali sfavorevoli non divulgate sull'emittente.

Cardlytics, Inc. (CDLX) presentó un aviso Form 144 notificando una propuesta de venta de 68.260 acciones ordinarias a través de Fidelity Brokerage Services por un valor total de $76.806,15. El documento indica que el número de acciones en circulación es 53.236.901 y señala una fecha aproximada de venta del 18/08/2025 en NASDAQ. Los valores fueron adquiridos como restricted stock vesting del emisor el 15/08/2025 y la naturaleza del pago se anota como compensación.

El declarante también informó una venta previa el 02/07/2025 de 6.725 acciones por unos ingresos brutos de $11.987,99. El expediente incluye la representación estándar de que el vendedor no tiene conocimiento de información adversa material no divulgada sobre el emisor.

Cardlytics, Inc. (CDLX)는 Form 144 공시를 통해 Fidelity Brokerage Services를 통해 68,260 보통주를 총액 $76,806.15에 매각할 예정임을 보고했습니다. 신고서에는 유통 주식수가 53,236,901주로 기재되어 있으며 NASDAQ에서의 대략적인 매각 예정일은 2025-08-18로 표시되어 있습니다. 해당 증권은 발행사로부터 2025-08-15restricted stock vesting으로 취득되었으며 지급 성격은 보상으로 명시되어 있습니다.

신고인은 또한 2025-07-026,725주를 매각하여 총수입 $11,987.99을 얻은 이전 거래를 보고했습니다. 신고서에는 판매자가 발행사에 관한 미공개 중요 불리 정보가 없다는 표준 진술이 포함되어 있습니다.

Cardlytics, Inc. (CDLX) a déposé un avis Form 144 signalant un projet de vente de 68 260 actions ordinaires via Fidelity Brokerage Services pour une valeur totale de 76 806,15 $. Le dépôt indique le nombre d'actions en circulation à 53 236 901 et mentionne une date approximative de vente au 18/08/2025 sur le NASDAQ. Les titres ont été acquis en tant que restricted stock vesting de l'émetteur le 15/08/2025 et la nature du paiement est indiquée comme rémunération.

Le déclarant a également signalé une vente antérieure le 02/07/2025 de 6 725 actions pour un produit brut de 11 987,99 $. Le dépôt comprend la déclaration standard selon laquelle le vendeur n'a pas connaissance d'informations défavorables importantes non divulguées concernant l'émetteur.

Cardlytics, Inc. (CDLX) hat ein Form-144-Meldeformular eingereicht, in dem ein geplanter Verkauf von 68.260 Stammaktien über Fidelity Brokerage Services mit einem Gesamtwert von $76.806,15 gemeldet wird. Die Einreichung gibt die Anzahl der ausstehenden Aktien mit 53.236.901 an und nennt ein ungefähres Verkaufsdatum am 18.08.2025 an der NASDAQ. Die Wertpapiere wurden am 15.08.2025 als restricted stock vesting vom Emittenten erworben, und die Zahlung wird als Vergütung angegeben.

Der Melder berichtete zudem über einen früheren Verkauf am 02.07.2025 von 6.725 Aktien mit Bruttoerlösen in Höhe von $11.987,99. Die Einreichung enthält die übliche Erklärung, dass dem Verkäufer keine nicht offengelegten, wesentlichen nachteiligen Informationen über den Emittenten bekannt sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR This Form 144 reports a routine officer/insider sale of vested restricted stock with no additional disclosures.

The notice documents a proposed sale of 68,260 common shares via Fidelity with an aggregate market value of $76,806.15 and notes a prior sale of 6,725 shares for $11,987.99. The shares were acquired as restricted stock vesting from the issuer and the filing contains the required attestation about material non-public information. The filing does not disclose any earnings, financing, litigation, or other events beyond the equity sales themselves.

TL;DR The filing is a standard insider sale notice tied to vested compensation; it contains no governance irregularities or additional disclosures.

The Form 144 lists the transaction details, broker, acquisition method (restricted stock vesting), and the seller's attestation regarding material information. No departures from standard disclosure practices are indicated within the notice.

Cardlytics, Inc. (CDLX) ha presentato un avviso Form 144 relativo a una proposta di vendita di 68.260 azioni ordinarie tramite Fidelity Brokerage Services per un valore complessivo di $76.806,15. Il deposito riporta il numero di azioni in circolazione pari a 53.236.901 e indica una data di vendita approssimativa del 18/08/2025 sul NASDAQ. I titoli sono stati acquisiti come restricted stock vesting dall'emittente il 15/08/2025 e la natura del pagamento è indicata come compenso.

Il dichiarante segnala inoltre una vendita precedente avvenuta il 02/07/2025 di 6.725 azioni per ricavi lordi di $11.987,99. Il deposito include la dichiarazione standard secondo cui il venditore non è a conoscenza di informazioni materiali sfavorevoli non divulgate sull'emittente.

Cardlytics, Inc. (CDLX) presentó un aviso Form 144 notificando una propuesta de venta de 68.260 acciones ordinarias a través de Fidelity Brokerage Services por un valor total de $76.806,15. El documento indica que el número de acciones en circulación es 53.236.901 y señala una fecha aproximada de venta del 18/08/2025 en NASDAQ. Los valores fueron adquiridos como restricted stock vesting del emisor el 15/08/2025 y la naturaleza del pago se anota como compensación.

El declarante también informó una venta previa el 02/07/2025 de 6.725 acciones por unos ingresos brutos de $11.987,99. El expediente incluye la representación estándar de que el vendedor no tiene conocimiento de información adversa material no divulgada sobre el emisor.

Cardlytics, Inc. (CDLX)는 Form 144 공시를 통해 Fidelity Brokerage Services를 통해 68,260 보통주를 총액 $76,806.15에 매각할 예정임을 보고했습니다. 신고서에는 유통 주식수가 53,236,901주로 기재되어 있으며 NASDAQ에서의 대략적인 매각 예정일은 2025-08-18로 표시되어 있습니다. 해당 증권은 발행사로부터 2025-08-15restricted stock vesting으로 취득되었으며 지급 성격은 보상으로 명시되어 있습니다.

신고인은 또한 2025-07-026,725주를 매각하여 총수입 $11,987.99을 얻은 이전 거래를 보고했습니다. 신고서에는 판매자가 발행사에 관한 미공개 중요 불리 정보가 없다는 표준 진술이 포함되어 있습니다.

Cardlytics, Inc. (CDLX) a déposé un avis Form 144 signalant un projet de vente de 68 260 actions ordinaires via Fidelity Brokerage Services pour une valeur totale de 76 806,15 $. Le dépôt indique le nombre d'actions en circulation à 53 236 901 et mentionne une date approximative de vente au 18/08/2025 sur le NASDAQ. Les titres ont été acquis en tant que restricted stock vesting de l'émetteur le 15/08/2025 et la nature du paiement est indiquée comme rémunération.

Le déclarant a également signalé une vente antérieure le 02/07/2025 de 6 725 actions pour un produit brut de 11 987,99 $. Le dépôt comprend la déclaration standard selon laquelle le vendeur n'a pas connaissance d'informations défavorables importantes non divulguées concernant l'émetteur.

Cardlytics, Inc. (CDLX) hat ein Form-144-Meldeformular eingereicht, in dem ein geplanter Verkauf von 68.260 Stammaktien über Fidelity Brokerage Services mit einem Gesamtwert von $76.806,15 gemeldet wird. Die Einreichung gibt die Anzahl der ausstehenden Aktien mit 53.236.901 an und nennt ein ungefähres Verkaufsdatum am 18.08.2025 an der NASDAQ. Die Wertpapiere wurden am 15.08.2025 als restricted stock vesting vom Emittenten erworben, und die Zahlung wird als Vergütung angegeben.

Der Melder berichtete zudem über einen früheren Verkauf am 02.07.2025 von 6.725 Aktien mit Bruttoerlösen in Höhe von $11.987,99. Die Einreichung enthält die übliche Erklärung, dass dem Verkäufer keine nicht offengelegten, wesentlichen nachteiligen Informationen über den Emittenten bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Cardlytics' Form 144 filed for CDLX report?

The filing reports a proposed sale of 68,260 common shares with aggregate market value of $76,806.15 to be sold on 08/18/2025 via Fidelity on NASDAQ.

How were the shares acquired that are being sold according to the Form 144?

The shares were acquired on 08/15/2025 as restricted stock vesting from the issuer, and the nature of payment is listed as compensation.

Has the filer sold Cardlytics shares recently before this proposed sale?

Yes. The filing lists a prior sale on 07/02/2025 of 6,725 common shares for gross proceeds of $11,987.99.

What outstanding share count does the Form 144 list for Cardlytics?

The filing lists 53,236,901 shares outstanding.

Which broker is named in the Form 144 for the planned sale?

The broker listed is Fidelity Brokerage Services LLC, address 900 Salem Street, Smithfield, RI 02917.
Cardlytics

NASDAQ:CDLX

CDLX Rankings

CDLX Latest News

CDLX Latest SEC Filings

CDLX Stock Data

55.90M
51.80M
2.95%
45.76%
12.09%
Advertising Agencies
Services-computer Programming, Data Processing, Etc.
Link
United States
ATLANTA